ARTICLE | Clinical News
MM-310: Ph I started
March 30, 2017 12:58 AM UTC
Merrimack began an open-label, U.S. Phase I trial to evaluate IV MM-310 on day 1 of each 21-day cycle. A dose-escalation part will determine the MTD of MM-310 alone in up to 34 patients. The trial wil...
BCIQ Company Profiles
BCIQ Target Profiles